Home/Pipeline/ARYNTA (lisdexamfetamine dimesylate) Oral Solution

ARYNTA (lisdexamfetamine dimesylate) Oral Solution

Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older

ApprovedActive

Key Facts

Indication
Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older
Phase
Approved
Status
Active
Company

About Azurity Pharmaceuticals

Azurity Pharmaceuticals is a US-based, private specialty pharma company founded in 2014, targeting overlooked patient needs with a portfolio of over 50 approved products. It leverages a 'Next-Gen Commercial Model' utilizing data, analytics, and AI-driven digital tools to enhance commercial reach and stakeholder engagement. The company has a significant global footprint and recently launched new proprietary products like Ferabright and ARYNTA, signaling a strategic shift beyond pure generics into branded specialty pharmaceuticals.

View full company profile